{"id":1192,"date":"2026-10-13T06:22:00","date_gmt":"2026-10-13T10:22:00","guid":{"rendered":"https:\/\/drugchatter.com\/insights\/?p=1192"},"modified":"2026-09-21T17:33:20","modified_gmt":"2026-09-21T21:33:20","slug":"when-your-fastest-growing-market-exists-outside-the-label","status":"publish","type":"post","link":"https:\/\/drugchatter.com\/insights\/when-your-fastest-growing-market-exists-outside-the-label\/","title":{"rendered":"When Your Fastest-Growing Market Exists Outside the Label"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

How semaglutide and tirzepatide built a combined obesity-and-diabetes franchise worth tens of billions of dollars largely on off-label and compounded demand \u2014 and what changed in 2025 and 2026 when the FDA and two manufacturers moved to close that pathway.<\/p>\n\n\n\n

The Short Answer<\/h2>\n\n\n\n

Ozempic and Mounjaro, both approved only for type 2 diabetes, spent their first several years on the market functioning as de facto obesity drugs for a large share of new patients, because the on-label obesity versions \u2014 Wegovy and Zepbound \u2014 were slower to reach the market, harder to get insurance to cover, and, for a two-year stretch, in short enough supply that compounding pharmacies filled the gap at a fraction of branded list price. That off-label and compounded demand did not just accompany the category’s growth; it built it. Beginning in late 2024, the FDA started dismantling the two legal pathways that had made mass compounding possible, and by April 2026 the agency had proposed permanently closing the remaining one. What is left is a case study in how a label gap can create, and then lose, a market.<\/p>\n\n\n\n

The Five Findings That Matter<\/h2>\n\n\n\n
    \n
  1. Off-label prescribing built the diabetes-brand side of the category.<\/strong> In a real-world data analysis of first-time GLP-1 prescriptions since January 2020, the health data company Truveta found that 56% of patients newly started on Ozempic or Mounjaro \u2014 both approved only for type 2 diabetes \u2014 did not have a T2D diagnosis, while 81% of patients started on Wegovy, which is approved specifically for chronic weight management, did have an obesity or overweight indication.[1]<\/sup><\/li>\n\n\n\n
  2. The off-label share of Ozempic prescribing has been falling, not rising.<\/strong> Reported figures put off-label Ozempic prescribing for weight loss at roughly 32% of prescriptions in 2022, dropping to about 19% by 2023, as Wegovy capacity and coverage expanded and patients moved to the on-label weight-management brand.[2]<\/sup><\/li>\n\n\n\n
  3. The category’s revenue now outweighs almost anything else in the industry.<\/strong> Eli Lilly’s tirzepatide franchise, Mounjaro and Zepbound, generated $36.5 billion in 2025, about 56% of the company’s total revenue, and in the third quarter of 2025 alone the combined brands brought in $10.1 billion \u2014 enough to make tirzepatide the world’s best-selling drug for that quarter, ahead of Merck’s Keytruda at $8.1 billion.[3][4]<\/sup><\/li>\n\n\n\n
  4. Compounded versions of these drugs generated hundreds of documented adverse events.<\/strong> As of early 2025, the FDA had received more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide, many involving patients drawing the wrong dose from multidose vials, some serious enough to require hospitalization.[5]<\/sup><\/li>\n\n\n\n
  5. The regulatory door that enabled mass compounding is now most of the way shut.<\/strong> The FDA resolved the tirzepatide shortage in December 2024 and the semaglutide shortage in February 2025, ending the legal basis for shortage-driven compounding, and in April 2026 proposed permanently excluding semaglutide, tirzepatide, and liraglutide from the separate bulk-compounding pathway that outsourcing facilities had been trying to use instead.[6][7]<\/sup><\/li>\n<\/ol>\n\n\n\n

    How the Off-Label Market Formed: A Timeline<\/h2>\n\n\n\n
    Date<\/th>Event<\/th><\/tr>
    December 2017<\/td>FDA approves Ozempic (semaglutide injection) for type 2 diabetes. Not indicated for weight loss.[8]<\/sup><\/td><\/tr>
    June 2021<\/td>FDA approves Wegovy (semaglutide 2.4 mg) for chronic weight management \u2014 the first semaglutide product indicated for obesity.<\/td><\/tr>
    March 2022 \/ August 2022<\/td>Wegovy and Ozempic strengths added to the FDA drug shortage list amid surging demand.[9]<\/sup><\/td><\/tr>
    May 2022<\/td>FDA approves Mounjaro (tirzepatide) for type 2 diabetes. Also added to the shortage list as demand surged.<\/td><\/tr>
    November 2023<\/td>FDA approves Zepbound (tirzepatide) for chronic weight management.<\/td><\/tr>
    December 2024<\/td>FDA resolves the tirzepatide shortage; separately approves Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity \u2014 the first drug approved for OSA.[10]<\/sup><\/td><\/tr>
    February 2025<\/td>FDA resolves the semaglutide shortage, starting the enforcement-discretion clock for compounders.[6]<\/sup><\/td><\/tr>
    April\u2013May 2025<\/td>Enforcement discretion for 503A pharmacies and 503B outsourcing facilities ends in stages for both semaglutide and tirzepatide, following unsuccessful litigation by the Outsourcing Facilities Association.[11]<\/sup><\/td><\/tr>
    December 2025 \/ January 2026<\/td>FDA approves an oral semaglutide 25 mg tablet version of Wegovy; Novo Nordisk launches it in January 2026.[3]<\/sup><\/td><\/tr>
    February 2026<\/td>TrumpRx, a federal direct-to-consumer pricing platform, launches, listing FDA-approved semaglutide and tirzepatide at $149\u2013$449 per month versus roughly $1,000\u2013$1,350 branded list price; Novo Nordisk sues telehealth company Hims & Hers over compounded semaglutide patent infringement.[12][13]<\/sup><\/td><\/tr>
    April 2026<\/td>FDA approves orforglipron (Foundayo), Eli Lilly’s oral small-molecule GLP-1, for obesity, and separately proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulk-compounding substances list.[14][7]<\/sup><\/td><\/tr>
    July 2026<\/td>Public comment period on the bulks-list exclusion closes; as of this writing, no final rule has been issued.[15]<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    What the Data Show: On-Label vs. Off-Label Prescribing<\/h2>\n\n\n\n

    The clearest evidence that this category’s early growth ran through off-label use comes from Truveta’s analysis of first-time prescriptions in its real-world data set. The pattern splits cleanly along indication lines: drugs approved for diabetes were mostly used for something else, and the drug approved for weight loss was mostly used as labeled.<\/p>\n\n\n\n

    Brand<\/th>Active ingredient<\/th>Manufacturer<\/th>FDA indication<\/th>Approval date<\/th>Reported off-label \/ on-label signal<\/th><\/tr>
    Ozempic<\/td>Semaglutide<\/td>Novo Nordisk<\/td>Type 2 diabetes<\/td>Dec 2017<\/td>56% of new Ozempic\/Mounjaro patients combined had no T2D diagnosis[1]<\/sup><\/td><\/tr>
    Mounjaro<\/td>Tirzepatide<\/td>Eli Lilly<\/td>Type 2 diabetes<\/td>May 2022<\/td><\/tr>
    Wegovy<\/td>Semaglutide 2.4 mg<\/td>Novo Nordisk<\/td>Chronic weight management<\/td>Jun 2021<\/td>81% of new patients had an obesity\/overweight diagnosis[1]<\/sup><\/td><\/tr>
    Zepbound<\/td>Tirzepatide<\/td>Eli Lilly<\/td>Weight management; obesity + moderate-to-severe OSA<\/td>Nov 2023 \/ Dec 2024 (OSA)<\/td>Launched after Truveta’s study window; no comparable published figure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    The reason the diabetes-indicated brands carried so much off-label volume is straightforward: for several years they were simply easier to get. Ozempic reached pharmacies four years before Wegovy, and even after Wegovy launched, insurers frequently covered semaglutide for a diabetes diagnosis while carving obesity-only coverage out of the benefit \u2014 a gap that pushed patients and prescribers toward the drug that was actually reimbursed, whatever the label said.<\/p>\n\n\n\n

    The Money: How a Label Gap Became a $36 Billion Franchise<\/h2>\n\n\n\n

    Tirzepatide’s revenue trajectory illustrates how fast this demand converted into commercial scale once supply caught up. Eli Lilly’s Mounjaro and Zepbound combined for $2.31 billion and $3.84 billion respectively in the first quarter of 2025 \u2014 the diabetes brand still outselling the obesity brand at that point \u2014 before the pair reached a combined $10.1 billion in the third quarter, overtaking Keytruda as the world’s top-selling drug for that quarter.[16][4]<\/sup> For full-year 2025, Mounjaro and Zepbound brought in $36.5 billion, or roughly 56% of Eli Lilly’s total revenue, and fourth-quarter 2025 revenue for the company overall rose 43% year over year to $19.3 billion.[3][17]<\/sup><\/p>\n\n\n\n

    \n

    The FDA’s own count puts documented adverse events tied to compounded GLP-1 products at more than 455 for semaglutide and more than 320 for tirzepatide as of early 2025 \u2014 a tally the agency says is dominated by dosing errors from multidose vials rather than manufacturing contamination alone.[5]<\/sup><\/p>\n<\/blockquote>\n\n\n\n

    Two 2026 developments are reshaping how that revenue is captured going forward. First, TrumpRx, a federal direct-to-consumer pricing platform that launched in February 2026, lists FDA-approved semaglutide tablets at $149\u2013$299 per month, semaglutide injections at $199\u2013$349, and tirzepatide injections at $299\u2013$449 \u2014 a fraction of branded list prices that had run $1,000 to $1,350 per month, and squarely aimed at the price gap that made compounding attractive in the first place.[13]<\/sup> Second, orforglipron (Foundayo), Eli Lilly’s oral small-molecule GLP-1 approved for obesity in April 2026, is priced at $149\u2013$399 per month through LillyDirect and $346 per month under Most Favored Nation pricing on TrumpRx, undercutting the injectable brands even before Medicare’s obesity coverage expansion, expected by mid-2026, takes effect.[14][18]<\/sup> A patient-advocacy analysis from I-MAK projects that the combined semaglutide and tirzepatide franchises could generate roughly $400 billion in additional U.S. revenue between 2025 and 2030, reaching about $470 billion in cumulative revenue by the end of the decade \u2014 a forecast worth treating as an advocacy-group estimate rather than a company guidance figure, but directionally consistent with the growth rates both manufacturers have already reported.[19]<\/sup><\/p>\n\n\n\n

    Closing the Loophole: FDA’s Shortage-to-Enforcement Pathway<\/h2>\n\n\n\n

    Compounding pharmacies can legally produce a copy of an FDA-approved drug under two distinct statutory pathways, and both of them intersected with the GLP-1 shortage. Section 503A covers state-licensed pharmacies compounding patient-specific prescriptions; section 503B covers larger “outsourcing facilities” that can compound in bulk without individual prescriptions, but only using substances on the FDA’s 503B bulks list or drugs currently on the drug shortage list.<\/p>\n\n\n\n

    Wegovy and Ozempic strengths first appeared on the shortage list in March and August 2022 respectively, with Mounjaro following as tirzepatide demand surged.[9]<\/sup> That shortage designation is what let thousands of 503A and 503B compounders sell semaglutide and tirzepatide copies at roughly $150\u2013$300 per month, undercutting branded pricing by two-thirds or more.[5]<\/sup> The FDA began unwinding that pathway once supply caught up: it declared the tirzepatide shortage resolved in October\u2013December 2024 and the semaglutide shortage resolved on February 21, 2025, each time triggering a wind-down period of enforcement discretion \u2014 503A pharmacies lost their exemption first, with 503B outsourcing facilities given until March 19, 2025 (tirzepatide) and May 22, 2025 (semaglutide) before the FDA said it would begin enforcing against shortage-based compounding.[6][11]<\/sup> The Outsourcing Facilities Association sued the FDA over both determinations; courts denied preliminary injunctions in each case, and a district court upheld the FDA’s tirzepatide decision in May 2025.[9]<\/sup><\/p>\n\n\n\n

    That left one theoretical pathway open: the 503B bulks list, which lets outsourcing facilities compound from bulk substances even without a shortage, if the FDA finds a genuine “clinical need.” On April 30, 2026, the FDA proposed finding no such need for semaglutide, tirzepatide, or liraglutide, which would foreclose bulk compounding of all three even if a future shortage were ever declared again.[7]<\/sup> FDA Commissioner Marty Makary framed the rationale around the basic principle that outsourcing facilities cannot lawfully compound from bulk substances once FDA-approved versions of a drug are available, absent a demonstrated clinical need.[7]<\/sup> The public comment period, originally set to close June 29, 2026, was extended a month to July 30, 2026 at commenters’ request; as of this writing, the FDA has not announced a final rule.[15]<\/sup> Notably, the proposal does not directly restrict 503A pharmacies, which operate under separate state board oversight and don’t rely on the bulks list \u2014 but those pharmacies lost their own shortage-based justification for compounding “essentially a copy” of the branded products back in 2025.[20]<\/sup><\/p>\n\n\n\n

    The Legal Front: Manufacturers vs. Telehealth and Compounders<\/h2>\n\n\n\n

    Regulatory enforcement has run alongside an unusually aggressive private litigation campaign. Novo Nordisk had filed more than 130 lawsuits across 40 states against telehealth companies and compounding pharmacies by mid-2025, obtaining 44 permanent injunctions along the way, and continued filing new waves of cases into 2026, including 14 additional suits in March 2026 targeting pharmacies and telehealth providers accused of steering patients toward compounded “semaglutide” under a personalization pretext that Novo says violates state corporate-practice-of-medicine rules.[20][21]<\/sup><\/p>\n\n\n\n

    The highest-profile case targets Hims & Hers. On February 9, 2026, Novo Nordisk sued the telehealth company for infringing U.S. Patent 8,129,343, which covers semaglutide’s molecular structure, after Hims launched a compounded oral semaglutide pill priced at roughly a third of Wegovy’s cost. Novo’s complaint states that its own testing found impurities as high as 86% in compounded injectable semaglutide and up to 75% in compounded oral versions \u2014 a quality gap the company argues creates a meaningful risk of immunogenic reactions, including anaphylaxis, and of incorrect active-ingredient dosing.[12][22]<\/sup> The same week, the FDA publicly signaled it would restrict GLP-1 active pharmaceutical ingredients used in non-approved compounded products, naming Hims specifically, and HHS’s General Counsel referred the company to the Department of Justice for potential criminal and Food, Drug and Cosmetic Act violations.[22]<\/sup> The FDA had already issued more than 55 warning letters to online sellers of compounded GLP-1 products in September 2025, and continued issuing further rounds of warning letters to telehealth marketers into 2026.[13][23]<\/sup><\/p>\n\n\n\n

    The enforcement pressure has produced at least one notable countersuit. A compounding pharmacy operating under the name Strive amended an antitrust complaint against Novo Nordisk and Eli Lilly in a Texas federal court, alleging the manufacturers entered into illegal agreements with telehealth companies to cut compounding pharmacies out of the market and that Eli Lilly improperly interfered with Strive’s business relationships and disparaged compounded products.[24]<\/sup> That case is a reminder that the story here isn’t simply “regulator closes loophole” \u2014 it’s an active fight over who gets to serve the price-sensitive segment of a market the branded manufacturers themselves helped create by under-pricing and under-supplying it for years.<\/p>\n\n\n\n

    What the Label Actually Says: Safety Signal Snapshot<\/h2>\n\n\n\n

    Every FDA-approved semaglutide and tirzepatide product \u2014 Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound \u2014 carries the same boxed warning: in rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors, including medullary thyroid carcinoma, at clinically relevant exposures, and whether that risk translates to humans has not been established. All of these products are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and labeling directs prescribers to counsel patients on tumor symptoms such as a neck mass, difficulty swallowing, or persistent hoarseness.[25][26]<\/sup><\/p>\n\n\n\n

    Product<\/th>Label section updated<\/th>Approximate date<\/th><\/tr>
    Wegovy<\/td>Indications and usage; dosage initiation\/escalation schedule; acute kidney injury due to volume depletion<\/td>August 2025<\/td><\/tr>
    Wegovy<\/td>Severe GI adverse reactions; pulmonary aspiration during general anesthesia or deep sedation<\/td>November 2024<\/td><\/tr>
    Ozempic<\/td>Warnings and precautions \u2014 severe gastrointestinal adverse reactions<\/td>October 2025<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    This is a class where the gap between “compounded” and “branded,” and between “on-label” and “off-label,” is not cosmetic. Compounded versions may use different salt forms of the active ingredient (semaglutide sodium or semaglutide acetate rather than the base compound used in the approved product), come in multidose vials that require patients to self-measure a dose the branded pen delivers automatically, and are not subject to the same manufacturing and impurity testing \u2014 a distinction that maps directly onto the adverse-event pattern the FDA has documented.[5][22]<\/sup><\/p>\n\n\n\n

    Where AI-Generated Answers Diverge from the Evidence<\/h2>\n\n\n\n

    No large-scale, published study has isolated how accurately AI chatbots distinguish on-label from off-label GLP-1 use, or branded from compounded formulations, specifically. What does exist is a broader warning sign: a study of AI chatbot responses to 50 general medical questions found that roughly half the answers across models were judged problematic, with Grok rated worst at 58% problematic, followed by ChatGPT at 52% and Meta AI at 50%, and researchers pointed to fine-tuning on human feedback as one driver of chatbots favoring answers that align with what the user seems to expect over what is actually correct.[27]<\/sup><\/p>\n\n\n\n

    That general finding matters more than usual for this drug class, because the questions people actually ask about semaglutide and tirzepatide sit at exactly the kind of intersection where a chatbot’s training data is least reliable: which brand is FDA-approved for which indication, whether a given dose is on-label, whether “compounded semaglutide” and “Ozempic” are legally and clinically interchangeable, and whether a given telehealth offer is even legal to fill. A useful way to organize the risk is by error type rather than by platform:<\/p>\n\n\n\n

    A working taxonomy of GLP-1 information errors in AI-generated answers<\/h4>\n\n\n\n
      \n
    • Indication conflation<\/strong> \u2014 describing Ozempic or Mounjaro as “approved for weight loss” without noting the off-label distinction from Wegovy or Zepbound.<\/li>\n\n\n\n
    • Formulation conflation<\/strong> \u2014 treating compounded and branded product as clinically and legally equivalent, without noting impurity, salt-form, or dosing-device differences.<\/li>\n\n\n\n
    • Regulatory-status lag<\/strong> \u2014 citing shortage-based compounding as currently legal after the FDA resolved the relevant shortage and enforcement discretion ended.<\/li>\n\n\n\n
    • Dosing-unit ambiguity<\/strong> \u2014 presenting a dose without clarifying units or delivery device, the same category of error the FDA links to real-world compounded-product adverse events.<\/li>\n<\/ul>\n\n\n\n

      This is the kind of drift that platforms built specifically to monitor how AI systems answer drug-related questions are designed to catch \u2014 tracking not just whether a brand is mentioned, but whether the surrounding claim matches the current label and current regulatory status as both keep moving. DrugChatter, for instance, is one such monitoring tool built around comparing AI-generated drug answers against authoritative sources like FDA labeling over time; it is a useful lens for spotting exactly this kind of indication or regulatory-status drift, though it is not a substitute for the underlying FDA and clinical evidence itself.<\/p>\n\n\n\n

      What This Means for Pharma Teams<\/h2>\n\n\n\n

      Medical Affairs<\/h3>\n\n\n\n

      The on-label\/off-label split shown in the Truveta data is a reminder that medical information requests about diabetes-indicated GLP-1s should assume a meaningful share of callers are using the drug for weight management, whether or not that’s stated. Field teams fielding questions about “switching from Ozempic to Wegovy” are often really fielding a coverage and access question, not a clinical equivalence question.<\/p>\n\n\n\n

      Pharmacovigilance<\/h3>\n\n\n\n

      The FDA’s compounded-product adverse-event counts \u2014 455-plus for semaglutide, 320-plus for tirzepatide \u2014 were dominated by dosing errors tied to multidose vials rather than the active ingredient itself.[5]<\/sup> PV teams monitoring signal volume for these molecules should expect the reported-event mix to keep shifting as compounded-product exposure declines and branded, auto-dosed pen exposure grows as a share of total use.<\/p>\n\n\n\n

      Regulatory Affairs<\/h3>\n\n\n\n

      The 503A\/503B distinction is not academic for anyone advising on compounding-adjacent business models: the April 2026 bulks-list proposal, if finalized, would foreclose 503B bulk compounding of these three molecules even under a future shortage declaration, while 503A pharmacies remain technically outside that specific rule but already lost their own shortage-based justification in 2025.[7][20]<\/sup><\/p>\n\n\n\n

      Brand and Commercial Teams<\/h3>\n\n\n\n

      TrumpRx and orforglipron’s direct-to-consumer pricing both target the exact price gap that made compounding attractive, at $149\u2013$449 per month against $1,000-plus branded list prices.[13][18]<\/sup> That is a pricing-strategy signal as much as a regulatory one: the compounding market didn’t grow because patients wanted an unapproved product, it grew because the approved product was priced and supplied in a way that left an opening.<\/p>\n\n\n\n

      FAQ<\/h2>\n\n\n\n

      Is it still legal to get compounded semaglutide or tirzepatide in 2026?<\/h3>\n\n\n\n

      Only in narrow circumstances. Broad, shortage-based compounding by both 503A pharmacies and 503B outsourcing facilities is no longer permitted after the FDA resolved the tirzepatide and semaglutide shortages in late 2024 and early 2025 and enforcement discretion periods expired through mid-2025.[6][11]<\/sup><\/p>\n\n\n\n

      Why were Ozempic and Mounjaro prescribed off-label so often?<\/h3>\n\n\n\n

      Both were approved years before their obesity-indicated counterparts (Wegovy and Zepbound) and, for a period, insurance was more likely to cover them under a diabetes diagnosis, so prescribers and patients used the drug that was actually accessible.[1]<\/sup><\/p>\n\n\n\n

      What’s the actual difference between Ozempic and Wegovy?<\/h3>\n\n\n\n

      They contain the same active ingredient, semaglutide, but are approved for different indications, dosed on different titration schedules, and marketed under different names \u2014 Ozempic for type 2 diabetes, Wegovy for chronic weight management.<\/p>\n\n\n\n

      Why did the FDA remove semaglutide and tirzepatide from the shortage list?<\/h3>\n\n\n\n

      The agency determined, after review of manufacturer, provider, and patient data, that supply could meet current and projected demand \u2014 for tirzepatide in December 2024 and for semaglutide in February 2025.[6][9]<\/sup><\/p>\n\n\n\n

      What health risks are specific to compounded versions of these drugs?<\/h3>\n\n\n\n

      Novo Nordisk’s own testing found impurities as high as 86% in compounded injectable semaglutide and 75% in compounded oral versions, and the FDA has linked hundreds of adverse event reports to dosing errors from self-measured, multidose compounded vials.[5][22]<\/sup><\/p>\n\n\n\n

      Is there a boxed warning on these drugs?<\/h3>\n\n\n\n

      Yes. Every FDA-approved semaglutide and tirzepatide product carries a boxed warning about thyroid C-cell tumors observed in rodent studies and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.[25][26]<\/sup><\/p>\n\n\n\n

      How big is the GLP-1 market now?<\/h3>\n\n\n\n

      Eli Lilly’s Mounjaro and Zepbound alone generated $36.5 billion in 2025, about 56% of the company’s revenue, and became the world’s best-selling drug franchise in the third quarter of that year.[3][4]<\/sup><\/p>\n\n\n\n

      What is TrumpRx and how does it affect GLP-1 pricing?<\/h3>\n\n\n\n

      TrumpRx is a federal direct-to-consumer pricing platform that launched in February 2026, listing FDA-approved semaglutide and tirzepatide at $149 to $449 per month, well below prior branded list prices of roughly $1,000 to $1,350.[13]<\/sup><\/p>\n\n\n\n

      Can AI chatbots be trusted for questions about these drugs?<\/h3>\n\n\n\n

      Not without verification. A study of chatbot answers to 50 general medical questions found about half were problematic across models tested, and the on-label\/off-label and branded\/compounded distinctions in this drug class are exactly the kind of nuance that kind of error tends to flatten.[27]<\/sup><\/p>\n\n\n\n

      Is there a newer, non-injectable option in this class?<\/h3>\n\n\n\n

      Yes. Novo Nordisk launched an oral semaglutide tablet version of Wegovy in January 2026, and the FDA approved Eli Lilly’s orforglipron (Foundayo), a different, non-peptide oral GLP-1, for obesity in April 2026.[3][14]<\/sup><\/p>\n\n\n\n

      Key Takeaways<\/h2>\n\n\n\n
        \n
      • Off-label use of diabetes-indicated GLP-1s (Ozempic, Mounjaro) was not a side effect of this market’s growth \u2014 it was a primary driver, with 56% of new patients in one real-world data analysis lacking a diabetes diagnosis.[1]<\/sup><\/li>\n\n\n\n
      • The obesity-indicated brands (Wegovy, Zepbound) were used on-label at a much higher rate (81% for Wegovy) once patients could access them.[1]<\/sup><\/li>\n\n\n\n
      • Compounding filled the supply-and-price gap during the 2022\u20132024 shortage years, generating hundreds of documented adverse events tied largely to dosing errors.[5]<\/sup><\/li>\n\n\n\n
      • The FDA closed the shortage-based compounding pathway in 2024\u20132025 and proposed closing the remaining bulk-compounding pathway in April 2026; a final rule has not yet been issued.[6][7][15]<\/sup><\/li>\n\n\n\n
      • Manufacturers have pursued the compounding market aggressively through litigation \u2014 more than 130 Novo Nordisk lawsuits by mid-2025 \u2014 while also being sued themselves over alleged anticompetitive coordination with telehealth companies.[20][24]<\/sup><\/li>\n\n\n\n
      • New pricing mechanisms (TrumpRx, LillyDirect, orforglipron) are now competing directly with the price point that made compounding attractive in the first place.[13][18]<\/sup><\/li>\n<\/ul>\n\n\n\n

        References<\/h2>\n\n\n\n
          \n
        1. Truveta. (2026). Ozempic, Wegovy, and Mounjaro: Prescribing trends.<\/em> https:\/\/www.truveta.com\/blog\/research\/ozempic-wegovy-and-mounjaro\/<\/li>\n\n\n\n
        2. Heally. (2026). Ozempic for weight loss in 2026: Is it still effective?<\/em> https:\/\/getheally.com\/patients\/news\/is-ozempic-becoming-yesterdays-weight-loss-drug<\/li>\n\n\n\n
        3. Yahoo Finance \/ Zacks. (2026). Lilly’s GLP-1 blockbusters drive 2025 revenue surge: What’s ahead?<\/em> https:\/\/finance.yahoo.com\/news\/lillys-glp-1-blockbusters-drive-134000159.html<\/li>\n\n\n\n
        4. BioPharma Dive. (2025). Lilly hikes revenue forecasts on booming obesity drug sales.<\/em> https:\/\/www.biopharmadive.com\/news\/lilly-third-quarter-2025-earnings-zepbound-mounjaro-obesity-sales\/804232\/<\/li>\n\n\n\n
        5. Pharmacy Times. (2026). FDA moves to permanently close the door on compounded GLP-1s.<\/em> https:\/\/www.pharmacytimes.com\/view\/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s<\/li>\n\n\n\n
        6. Foley & Lardner. (2025). GLP-1 Drugs: FDA removes semaglutide from the drug shortage list.<\/em> https:\/\/www.foley.com\/insights\/publications\/2025\/02\/glp-1-drugs-fda-removes-semaglutide-from-drug-shortage-list\/<\/li>\n\n\n\n
        7. U.S. Food and Drug Administration. (2026). FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list.<\/em> https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list<\/li>\n\n\n\n
        8. Harris Beach Murtha. (2026). GLP-1 weight-loss drugs off shortage list; deadlines to stop compounding.<\/em> https:\/\/www.harrisbeachmurtha.com\/insights\/glp-1-weight-loss-drugs-off-shortage-list-deadlines-to-stop-compounding\/<\/li>\n\n\n\n
        9. JD Supra \/ Burr & Forman; McDermott Will & Schulte. (2025). GLP-1 Update: Court backs FDA in tirzepatide compounding case; The FDA removes semaglutide from the drug shortage list.<\/em> https:\/\/www.jdsupra.com\/topics\/supply-shortages<\/li>\n\n\n\n
        10. Sleep Foundation. (2026). Zepbound approved to treat obstructive sleep apnea.<\/em> https:\/\/www.sleepfoundation.org\/sleep-apnea\/zepbound-approved-to-treat-obstructive-sleep-apnea<\/li>\n\n\n\n
        11. U.S. Food and Drug Administration. (2025). FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.<\/em> https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize<\/li>\n\n\n\n
        12. FindLaw. (2026). Novo Nordisk takes telehealth company to patent court over semaglutide knockoffs.<\/em> https:\/\/www.findlaw.com\/legalblogs\/courtside\/novo-nordisk-takes-telehealth-company-to-patent-court-over-semaglutide-knockoffs\/<\/li>\n\n\n\n
        13. Pharmacy Times. (2026). FDA and Novo Nordisk warned of GLP-1 telehealth compounding takedown. What’s next?<\/em> https:\/\/www.pharmacytimes.com\/view\/fda-and-novo-nordisk-warned-of-glp-1-telehealth-compounding-take-down-what-s-next-<\/li>\n\n\n\n
        14. PatientCareOnline. (2026). FDA approves orforglipron, first oral GLP-1 receptor agonist for weight loss with no food or water restrictions.<\/em> https:\/\/www.patientcareonline.com\/view\/fda-approves-orforglipron-first-oral-glp-1-receptor-agonist-for-weight-loss-with-no-food-or-water-restrictions<\/li>\n\n\n\n
        15. US Health Digest. (2026). FDA moves to make the compounded GLP-1 ban permanent: Comment period closed, no final rule yet.<\/em> https:\/\/ushealthdigest.com\/fda-compounded-glp1-ban-2026\/<\/li>\n\n\n\n
        16. Barchart. (2025). LLY’s Q1 earnings miss; Mounjaro, Zepbound drive sales.<\/em> https:\/\/www.barchart.com\/story\/news\/32165376\/llys-q1-earnings-miss-mounjaro-zepbound-drive-sales-stock-down<\/li>\n\n\n\n
        17. BioPharma Dive. (2026). Lilly soars again as fast-selling weight loss drugs top Wall Street projections.<\/em> https:\/\/www.biopharmadive.com\/news\/lilly-earnings-guidance-q4-2025-obesity-drugs\/811317\/<\/li>\n\n\n\n
        18. Close Concerns. (2026). Lilly prepares to launch orforglipron for obesity; FDA decision expected imminently.<\/em> https:\/\/cckb.closeconcerns.com\/r\/42fe8d12<\/li>\n\n\n\n
        19. I-MAK. (2026). The heavy price of GLP-1 drugs: How financialization drives pharmaceutical patent abuse and health inequities for GLP-1 therapies.<\/em> https:\/\/www.i-mak.org\/glp-1\/<\/li>\n\n\n\n
        20. HCH Lawyers. (2026). Novo Nordisk, Eli Lilly sending cease-and-desist letters over compounded semaglutide.<\/em> https:\/\/www.hchlawyers.com\/blog\/2026\/february\/novo-nordisk-eli-lilly-sending-cease-and-desist-\/<\/li>\n\n\n\n
        21. American Med Spa Association. (2026). Novo Nordisk files 14 new lawsuits over compounded semaglutide.<\/em> https:\/\/www.americanmedspa.org\/news\/novo-nordisk-files-14-new-lawsuits-over-compounded-semaglutide\/<\/li>\n\n\n\n
        22. Novo Nordisk. (2026). Company statement on litigation against Hims & Hers.<\/em> https:\/\/www.novomedlink.com\/content\/dam\/novomedlink\/semaglutide\/02-09-2026-company-statement.pdf<\/li>\n\n\n\n
        23. Drug Topics. (2026). FDA issues warnings to 30 telehealth companies against illegal marketing of compounded GLP-1 medications.<\/em> https:\/\/www.drugtopics.com\/view\/fda-issues-warnings-to-30-telehealth-companies-against-illegal-marketing-of-compounded-glp-1-medications<\/li>\n\n\n\n
        24. U.S. Securities and Exchange Commission. (2026). Novo Nordisk A\/S, Form 6-K.<\/em> https:\/\/www.sec.gov\/Archives\/edgar\/data\/0000353278\/000035327826000018\/caq12026.htm<\/li>\n\n\n\n
        25. U.S. Food and Drug Administration. (2025). Wegovy (semaglutide) prescribing information.<\/em> https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215256s023lbl.pdf<\/li>\n\n\n\n
        26. U.S. Food and Drug Administration. (2026). Ozempic (semaglutide) prescribing information.<\/em> https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/209637s038lbl.pdf<\/li>\n\n\n\n
        27. Yahoo Finance UK. (2026). AI chatbots often ‘hallucinate’ and give inaccurate medical information \u2014 study.<\/em> https:\/\/uk.finance.yahoo.com\/news\/ai-chatbots-often-hallucinate-inaccurate-223000944.html<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

          How semaglutide and tirzepatide built a combined obesity-and-diabetes franchise worth tens of billions of dollars largely on off-label and compounded […]<\/p>\n","protected":false},"author":1,"featured_media":1216,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1192","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"modified_by":"DrugChatter","_links":{"self":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1192","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/comments?post=1192"}],"version-history":[{"count":2,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1192\/revisions"}],"predecessor-version":[{"id":1217,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/posts\/1192\/revisions\/1217"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media\/1216"}],"wp:attachment":[{"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/media?parent=1192"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/categories?post=1192"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/drugchatter.com\/insights\/wp-json\/wp\/v2\/tags?post=1192"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}